藥明康德(02359.HK)擬採納2022年H股獎勵信託計劃 上限為20億港元
格隆匯8月15日丨藥明康德(02359.HK)公佈,董事會於2022年8月15日舉行的董事會會議上議決建議採納2022年計劃。2022年計劃須經股東於臨時股東大會批准後,方可生效。
2022年計劃的獎勵股份來源須為受託人根據公司指示及2022年計劃規則相關條文通過市場內交易以現行市價收購的H股。
根據2022年計劃規則,計劃上限須為受託人可不時按現行市價通過市場內交易以不超過20億港元的資金收購最高數目的H股,惟無論如何受託人所收購H股的最高數目應由董事會及╱或授權人士(根據股東授予的授權)釐定,且不得超過2021年計劃的受託人為履行據此授予的獎勵而按照公司指示所收購H股總數上浮10%(含10%)後的數量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.